BioWorld

Nov. 9, 2015

View Archived Issues

New HIV therapeutics benefit from two decades of research

The FDA approval of Gilead Sciences Inc.'s once-daily, single-tablet regimen branded Genvoya on its Nov. 5 PDUFA date adds another point on the development trajectory graph of antiviral therapies. (See BioWorld Today, Nov.6, 2015.) Read More

Most me-too drugs start before risk is abated

There can be only one first-in-class drug. Every drug developed after that is a me-too drug in the most basic sense. Read More

Week in review

Read More

Week in Washington

Read More

Word on the street

Read More

The week's biggest gainers and losers

Read More

BioWorld stock report for public biotechnology companies

Read More

BioWorld Stock Index 2015

Read More

Nasdaq Stock Index 2015

Read More

Money raised by biotech: Jan. 1 - Nov. 5, 2015

Read More

Public financing of biotechnology companies: Commenced trading in October 2015

Read More

Public financing of biotechnology companies: Filed and pending IPOs

Read More

Other financings of public biotechnology companies: October 2015

Read More

2015 top financings of public companies

Read More

2015 top financings of private companies

Read More

Venture capital & other investments in private biotechnology companies: October 2015

Read More

Milestone payments from corporate partners: October 2015

Read More

Money raised by biotech in 2015 vs. 2014

Read More